Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone240-631-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$782.40 million
Profitability
Miscellaneous
Employees1,705
Next Earnings Date11/6/2019 (Confirmed)
OptionableOptionable
Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions
What is Emergent Biosolutions' stock symbol?
Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."
How will Emergent Biosolutions' stock buyback program work?
Emergent Biosolutions declared that its board has initiated a share repurchase plan on Friday, March 23rd 2018, which allows the company to buyback $50,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its stock is undervalued.
How were Emergent Biosolutions' earnings last quarter?
Emergent Biosolutions Inc (NYSE:EBS) announced its quarterly earnings data on Thursday, August, 1st. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by $0.04. The biopharmaceutical company earned $243.20 million during the quarter, compared to analysts' expectations of $217.94 million. Emergent Biosolutions had a negative net margin of 2.04% and a positive return on equity of 6.68%. Emergent Biosolutions's revenue was up 10.4% on a year-over-year basis. During the same period last year, the company earned $1.07 earnings per share. View Emergent Biosolutions' Earnings History.
When is Emergent Biosolutions' next earnings date?
How can I listen to Emergent Biosolutions' earnings call?
Emergent Biosolutions will be holding an earnings conference call on Wednesday, November 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Emergent Biosolutions issued on next quarter's earnings?
Emergent Biosolutions issued an update on its third quarter 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $245-275 million.
What price target have analysts set for EBS?
8 brokers have issued 1-year price objectives for Emergent Biosolutions' shares. Their predictions range from $60.00 to $80.00. On average, they expect Emergent Biosolutions' stock price to reach $70.25 in the next twelve months. This suggests a possible upside of 27.9% from the stock's current price. View Analyst Price Targets for Emergent Biosolutions.
What is the consensus analysts' recommendation for Emergent Biosolutions?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Emergent Biosolutions.
What are Wall Street analysts saying about Emergent Biosolutions stock?
Here are some recent quotes from research analysts about Emergent Biosolutions stock:
- 1. Cantor Fitzgerald analysts commented, ". Post 1Q19, we reiterate our Overweight rating and our 12- month price target of $75. EBS continues to be the leader in the biodefense field, and the acquisition of Adapt and PaxVax leverage the company’s historical expertise, while further diversifying revenue away from BioThrax. We continue to believe the company’s business is a lot more durable than the Street is giving it credit for, and we expect Emergent to extend a number of its current contracts beyond current estimates, as well as bring some significant pipeline product to market over time. Emergent does not have the risk of commercial insurance reimbursement or payer pricing pressures on the majority of its portfolio." (5/2/2019)
- 2. According to Zacks Investment Research, "Emergent BioSolutions' recent acquisitions of PaxVax and Adapt Pharma have expanded the company’s presence in the public health threats market. Its anthrax vaccine, NuThrax’s regulatory application is under review, with a decision expected in the first half of 2019. We are positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it resulted in reduction of the cost structure. Notably, the company derives majority of its revenues from BioThrax sales. Hence, its sole dependence on BioThrax for revenues is a headwind. Moreover, Emergent depends on certain single-source suppliers for key materials and services, which are necessary for manufacturing BioThrax. This, in turn, raises a concern. Shares of the company have underperformed the industry so far this year. Estimates have narrowed ahead of Q1 earnings. Emergent has a mixed record of earnings surprises in the recent quarters." (4/8/2019)
Has Emergent Biosolutions been receiving favorable news coverage?
News coverage about EBS stock has trended somewhat positive this week, according to InfoTrie. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Emergent Biosolutions earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Emergent Biosolutions.
Are investors shorting Emergent Biosolutions?
Emergent Biosolutions saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 2,790,000 shares, a decrease of 17.0% from the August 30th total of 3,360,000 shares. Based on an average daily trading volume, of 432,700 shares, the days-to-cover ratio is currently 6.4 days. Approximately 6.5% of the company's stock are short sold. View Emergent Biosolutions' Current Options Chain.
Who are some of Emergent Biosolutions' key competitors?
Some companies that are related to Emergent Biosolutions include Array Biopharma (ARRY), Mylan (MYL), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Ionis Pharmaceuticals (IONS), SAGE Therapeutics (SAGE), Perrigo (PRGO), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT) and Beigene (BGNE).
What other stocks do shareholders of Emergent Biosolutions own?
Who are Emergent Biosolutions' key executives?
Emergent Biosolutions' management team includes the folowing people:
- Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 61)
- Mr. Robert G. Kramer Sr., CEO, Pres & Director (Age 62)
- Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 55)
- Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 46)
- Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 48)
Who are Emergent Biosolutions' major shareholders?
Emergent Biosolutions' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.58%), Cambiar Investors LLC (0.08%), Envestnet Asset Management Inc. (0.07%), State of Alaska Department of Revenue (0.07%), Nisa Investment Advisors LLC (0.07%) and Assenagon Asset Management S.A. (0.03%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.
Which institutional investors are selling Emergent Biosolutions stock?
EBS stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Cambiar Investors LLC, Meeder Asset Management Inc., Financial Gravity Wealth Inc. and Envestnet Asset Management Inc.. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, Kathryn C Zoon and Sue Bailey. View Insider Buying and Selling for Emergent Biosolutions.
Which institutional investors are buying Emergent Biosolutions stock?
EBS stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Assenagon Asset Management S.A., Campbell & CO Investment Adviser LLC, Nisa Investment Advisors LLC, Capital Asset Advisory Services LLC and Outlook Wealth Advisors LLC. View Insider Buying and Selling for Emergent Biosolutions.
How do I buy shares of Emergent Biosolutions?
Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Emergent Biosolutions' stock price today?
One share of EBS stock can currently be purchased for approximately $54.91.
How big of a company is Emergent Biosolutions?
Emergent Biosolutions has a market capitalization of $2.83 billion and generates $782.40 million in revenue each year. The biopharmaceutical company earns $62.70 million in net income (profit) each year or $2.33 on an earnings per share basis. Emergent Biosolutions employs 1,705 workers across the globe.View Additional Information About Emergent Biosolutions.
What is Emergent Biosolutions' official website?
How can I contact Emergent Biosolutions?
Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]
MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)
MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
